Dextromethorphan
This article was originally published in The Tan Sheet
Executive Summary
CHPA plans to launch educational programs to deter inappropriate use of OTC cough remedy active ingredient in the Spring or Summer 2003. In Nov. 20 statement, trade group notes dextromethorphan "does not produce physical addiction, lose effectiveness through increased tolerance or cause withdrawal, even in high experimental doses." Statement responds to local news reports describing teenagers' abuse of dextromethorphan, CHPA says...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.